Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum + lactobacillus acidophilus + lactobacillus plantarum
- Development stage
- Unknown
- Lead developer
- Shenzhen People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This drug is a probiotic combination therapy consisting of three live bacterial strains: *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Lactobacillus plantarum*. It is utilized as a live biotherapeutic to restore intestinal microbial balance and enhance gut mucosal barrier function. In clinical settings, particularly for patients undergoing elective colorectal surgery, perioperative administration of this combination has been shown to reduce bacterial translocation, improve gut permeability by upregulating mucosal tight junction proteins, and decrease the incidence of infectious complications and postoperative diarrhea. The mechanism involves benefiting the fecal microbiota and maintaining the integrity of the gut barrier, thereby preventing the systemic entry of enteropathogenic bacteria.
- Other names
- bifidobacterium longum, lactobacillus acidophilus and lactobacillus plantarumB. longum + L. acidophilus + L. plantarum
02
Targets
OCLN (Occludin)
Beyond the preview
Go deeper on bifidobacterium longum + lactobacillus acidophilus + lactobacillus plantarum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum + lactobacillus acidophilus + lactobacillus plantarum.